Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15396012 | 0.91 | PIK3CD (0.42) | PIK3CDEPHX2 | |
| SCHEMBL15396013 | 0.89 | PIK3CD (0.40) | PIK3CD | |
| SCHEMBL22534918 | 0.87 | PIK3CD (0.46) | PIK3CDEPHX2 | |
| SCHEMBL19657880 | 0.84 | PIK3CD (0.44) | PIK3CDEPHX2 | |
| SCHEMBL15033772 | 0.83 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL22534932 | 0.81 | PIK3CD (0.44) | PIK3CDEPHX2 | |
| SCHEMBL22534917 | 0.80 | PIK3CD (0.43) | PIK3CDEPHX2 | |
| SCHEMBL15033769 | 0.78 | PIK3CD (0.50) | PIK3CD | |
| SCHEMBL21897278 | 0.78 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL15033746 | 0.78 | PIK3CD (0.38) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160115175-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160083395-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9233974-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150361087-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2013-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-20160115175-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-20150361087-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
| US-20160083395-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PIK3CD 785/4885EPHX2 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.